• Publications
  • Influence
Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new
PURPOSE Response Evaluation Criteria in Solid Tumors (RECIST) are insensitive in evaluating gastrointestinal stromal tumors (GISTs) treated with imatinib. This study evaluates whether computedExpand
  • 1,221
  • 79
  • PDF
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine
PURPOSE To assess potential differences in progression-free or overall survival when imatinib mesylate is administered to patients with incurable gastrointestinal stromal tumors (GIST) at a standardExpand
  • 823
  • 45
CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings.
OBJECTIVE We correlated changes in tumor density on CT with changes in glucose metabolism, or the maximum standardized uptake value (SUV(max)), on FDG PET and sought to develop CT imaging criteriaExpand
  • 414
  • 27
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.
The NCCN Soft Tissue Sarcoma Guidelines include a subsection about treatment recommendations for gastrointestinal stromal tumors (GISTs). The standard of practice rapidly changed after theExpand
  • 556
  • 20
We should desist using RECIST, at least in GIST.
PURPOSE Response Evaluation Criteria in Solid Tumors (RECIST) are insensitive in evaluating imatinib-treated gastrointestinal stromal tumors (GISTs). Response by Choi criteria, a 10% decrease in sizeExpand
  • 509
  • 19
Prognostic factors for patients with localized soft‐tissue sarcoma treated with conservation surgery and radiation therapy
Prognostic factors for patients with soft‐tissue sarcoma who are treated with conservative surgery and radiation are documented poorly.
  • 431
  • 18
Extraskeletal osteosarcoma. A clinicopathologic review of 26 cases
The clinical records and histopathologic features in 26 cases of extraskeletal osteosarcoma (ESOS) diagnosed at M. D. Anderson Cancer Center (Houston) between 1950 and 1987 were reviewed.Expand
  • 229
  • 16
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study
PURPOSE Imatinib mesylate is standard treatment for patients who have advanced gastrointestinal stromal tumor (GIST), but not all patients benefit equally. In previous studies, GIST genotypeExpand
  • 494
  • 15
  • PDF
Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
Soft tissue sarcomas (STS) are rare solid tumors of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, bloodExpand
  • 497
  • 13
Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.
PURPOSE The addition of cytokines to chemotherapy has produced encouraging results in advanced melanoma. In this phase III trial, we compared the effects of chemotherapy (cisplatin, vinblastine, andExpand
  • 352
  • 11